Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

被引：0
|
作者：
McKean, M. [1 ]
Barve, M. [2 ]
Hong, D. [3 ]
Parikh, A. [4 ]
Rosen, E. [5 ]
Yang, J. [6 ]
Picard, R. [6 ]
Yi, J. [6 ]
Brail, L. [6 ]
Vecchio, D. [6 ]
Meniawy, T. [7 ]
John, T. [8 ]
Wang, J. [9 ]
机构：
[1] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[2] Mary Crowley Canc Res, Res Oncol, Dallas, TX USA
[3] MD Anderson, Invest Canc Therapeut ICT, Houston, TX USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[6] Erasca Inc, San Diego, CA USA
[7] Linear Clin Res & Univ Western Australia, Med Oncol, Nedlands, WA, Australia
[8] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[9] Florida Cancers Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
95
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [21] A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
    Molife, L. Rhoda
    Dean, Emma Jane
    Blanco-Codesido, Montserrat
    Krebs, Matthew G.
    Brunetto, Andre T.
    Greystoke, Alastair Peter
    Daniele, Gennaro
    Lee, Lucy
    Kuznetsov, Galina
    Myint, Khin Than
    Wood, Karen
    de las Heras, Begona
    Ranson, Malcolm Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6284 - 6294
  • [22] Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors
    Borad, M. J.
    Akerele, C. E.
    Ramanathan, R. K.
    Northfelt, D. W.
    Reyderman, L.
    Verbel, D.
    Feit, K.
    Von Hoff, D. D.
    Tibes, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors
    Meng, Yanchun
    Zhang, Jian
    Zhao, Chuanhua
    Cheng, Ying
    Zhu, Liming
    Song, Zhengbo
    Xu, Nong
    Wang, Zhen
    Wang, Yanping
    Du, Yiqun
    Jing, Deqiang
    Chen, Dinglu
    Qu, Qiaofeng
    Zhao, Xiwen
    Li, Wei
    Lu, Qiying
    Tian, Wenzhi
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
    Shapiro, Geoffrey I.
    Do, Khanh T.
    Tolaney, Sara M.
    Hilton, John F.
    Cleary, James M.
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Cai, Dongpo
    Downey, Elizabeth
    Pruitt-Thompson, Solida
    Barry, Suzanne M.
    Kochupurakkal, Bose
    Geradts, Joseph
    Unitt, Christine
    D'Andrea, Alan D.
    Muzikansky, Alona
    Piekarz, Richard
    Doyle, L. Austin
    Supko, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [25] Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors
    Infante, Jeffrey R.
    Dees, E. Claire
    Olszanski, Anthony J.
    Dhuria, Shyeilla V.
    Sen, Suman
    Cameron, Scott
    Cohen, Roger B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3103 - +
  • [26] MULTICENTER, DOSE-ESCALATION STUDY OF THE INVESTIGATIONAL DRUG TAK-733, AN ORAL MEK INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE 1 RESULTS
    Adjei, A. A.
    LoRusso, P. M.
    Ribas, A.
    Sosman, J. A.
    Dy, G. K.
    Chmielowski, B.
    Lipman, P.
    Zhou, X.
    Gangolli, E.
    Bozon, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 158 - 158
  • [27] Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: Preliminary results
    Jones, S. F.
    Burris, H. A., III
    Dumez, H.
    Infante, J. R.
    Fowst, C.
    Gerletti, P.
    Xu, H.
    Jakubczak, J.
    Mellaerts, N.
    Schoffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Preliminary results of a Phase I accelerated dose-escalation, pharmacokinetic and pharmacodynamic study of PF-03814735, an oral Aurora kinase A and B inhibitor, in patients with advanced solid tumors
    Schoeffski, P.
    Dumez, H.
    Jones, S. F.
    Fowst, C.
    Gerletti, P.
    Xu, H.
    Jakubczak, J.
    Infante, J.
    Mellaerts, N.
    Burris, H. A.
    EJC SUPPLEMENTS, 2008, 6 (12): : 91 - 91
  • [29] Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study
    Xu, Jian Ming
    Wang, Yan
    Chen, Yu Ling
    Jia, Ru
    Li, Jie
    Gong, Ji Fang
    Li, Jing
    Qi, Chuan
    Hua, Ye
    Tan, Cui Rong
    Wang, Jian
    Li, Ke
    Sai, Yang
    Zhou, Feng
    Ren, Yong Xin
    Qing, Wei Guo
    Jia, Hong
    Su, Wei Guo
    Shen, Lin
    ONCOTARGET, 2017, 8 (26) : 42076 - 42086
  • [30] BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
    Patel, Manish R.
    Juric, Dejan
    Henick, Brian S.
    Duska, Linda R.
    Wu, Rentian
    Guo, Jian
    Zhang, Hui
    Newberry, Kate
    Rinne, Mikael
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345